Special Issue "Marine Compounds and Cancer"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 31 January 2015

Special Issue Editors

Guest Editor
Dr. Friedemann Honecker
Oncology and Hematology, Oncolgy Centre, University Hospital Hamburg-Eppendorf, Germany
E-Mail: f.honecker@uke.de
Phone: +49 40 741052960
Fax: +49 40 741058054
Interests: oncology; cancer; tumor biology, marine natural product bioactivity

Guest Editor
Dr. Sergey A. Dyshlovoy
Laboratory of Marine Natural Products Chemistry, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, Vladivostok, Russia
E-Mail: dyshlovoy@gmail.com
Phone: +7 423 2311168
Fax: +7 423 2314050
Interests: marine natural products; molecular mechanism of anticancer activity; carcinogenesis; drug target identification and validation; proteomics

Special Issue Information

Dear Colleagues,

In Western countries, cancer is among the most frequent causes of death. Despite striking advances in cancer therapy, especially by the so called “targeted agents”, there is still an urgent need for new drugs in oncology. Hope comes from the marine environment, which is a rich source of natural compounds showing anti-cancer activity. To date, three marine cytotoxic substances, namely cytarabine, trabectidine, and eribulin, have made it into clinical routine. Many more are in all phases of clinical testing, and a plethora of substances has already been examined for in vitro and in vivo activity.

Interestingly, more and more precise research tools allow the dissection of the molecular mode of action of these cytotoxic substances, thereby uncovering the specific drug targets in cancer cells. This development will blur the edges between “targeted” and “untargeted” therapy, and will hopefully lead to a more directed use of cancer medicine (based on a molecular rationale of activity) in the future.

This special issue in Marine Drugs will cover the whole scope from agents with cancer-preventive activity, to novel and previously characterized compounds with anti-cancer activity, both in vitro and in vivo, and the latest status of clinical development from drug trials. In addition, focus will be placed on current shortfalls and possible strategies in the area of marine anti-cancer drug development.

Dr. Friedemann Honecker
Dr. Sergey A. Dyshlovoy
Guest Editors

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).

Keywords

  • cancer
  • marine natural compounds and their derivatives
  • marine toxins
  • drug discovery
  • cancer-preventive activity
  • molecular effects
  • molecular targets
  • toxicology
  • xenograft models

Published Papers (22 papers)

by
Mar. Drugs 2014, 12(3), 1377-1389; doi:10.3390/md12031377
Received: 1 November 2013; in revised form: 17 January 2014 / Accepted: 27 February 2014 / Published: 7 March 2014
Show/Hide Abstract | PDF Full-text (274 KB) | HTML Full-text | XML Full-text

by
Mar. Drugs 2014, 12(2), 851-870; doi:10.3390/md12020851
Received: 15 November 2013; in revised form: 31 December 2013 / Accepted: 10 January 2014 / Published: 28 January 2014
Show/Hide Abstract | PDF Full-text (765 KB) | HTML Full-text | XML Full-text

by ,  and
Mar. Drugs 2014, 12(2), 719-733; doi:10.3390/md12020719
Received: 29 November 2013; in revised form: 13 January 2014 / Accepted: 14 January 2014 / Published: 27 January 2014
Show/Hide Abstract | Cited by 1 | PDF Full-text (649 KB) | HTML Full-text | XML Full-text

by  and
Mar. Drugs 2014, 12(2), 636-671; doi:10.3390/md12020636
Received: 3 December 2013; in revised form: 14 January 2014 / Accepted: 15 January 2014 / Published: 27 January 2014
Show/Hide Abstract | PDF Full-text (1170 KB) | HTML Full-text | XML Full-text

by , , ,  and
Mar. Drugs 2014, 12(1), 279-299; doi:10.3390/md12010279
Received: 12 November 2013; in revised form: 26 December 2013 / Accepted: 27 December 2013 / Published: 16 January 2014
Show/Hide Abstract | PDF Full-text (796 KB) | HTML Full-text | XML Full-text | Supplementary Files
abstract graphic

by  and
Mar. Drugs 2014, 12(1), 255-278; doi:10.3390/md12010255
Received: 5 December 2013; in revised form: 17 December 2013 / Accepted: 7 January 2014 / Published: 14 January 2014
Show/Hide Abstract | Cited by 2 | PDF Full-text (501 KB) | HTML Full-text | XML Full-text
abstract graphic

by , , ,  and
Mar. Drugs 2014, 12(1), 54-68; doi:10.3390/md12010054
Received: 18 October 2013; in revised form: 28 November 2013 / Accepted: 9 December 2013 / Published: 24 December 2013
Show/Hide Abstract | PDF Full-text (1309 KB) | HTML Full-text | XML Full-text

by , ,  and
Mar. Drugs 2014, 12(1), 17-35; doi:10.3390/md12010017
Received: 30 October 2013; in revised form: 30 November 2013 / Accepted: 4 December 2013 / Published: 24 December 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (719 KB) | HTML Full-text | XML Full-text
abstract graphic

by ,  and
Mar. Drugs 2013, 11(12), 5130-5147; doi:10.3390/md11125130
Received: 10 October 2013; in revised form: 27 November 2013 / Accepted: 3 December 2013 / Published: 16 December 2013
Show/Hide Abstract | PDF Full-text (348 KB) | HTML Full-text | XML Full-text

by , , ,  and
Mar. Drugs 2013, 11(12), 5063-5086; doi:10.3390/md11125063
Received: 1 October 2013; in revised form: 30 November 2013 / Accepted: 2 December 2013 / Published: 13 December 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (1299 KB) | HTML Full-text | XML Full-text
abstract graphic

by , ,  and
Mar. Drugs 2013, 11(12), 4876-4901; doi:10.3390/md11124876
Received: 31 October 2013; in revised form: 21 November 2013 / Accepted: 22 November 2013 / Published: 2 December 2013
Show/Hide Abstract | PDF Full-text (500 KB) | HTML Full-text | XML Full-text

by , , , , ,  and
Mar. Drugs 2013, 11(12), 4858-4875; doi:10.3390/md11124858
Received: 30 August 2013; in revised form: 26 October 2013 / Accepted: 5 November 2013 / Published: 2 December 2013
Show/Hide Abstract | PDF Full-text (911 KB) | HTML Full-text | XML Full-text | Supplementary Files
abstract graphic

by , , ,  and
Mar. Drugs 2013, 11(11), 4267-4278; doi:10.3390/md11114267
Received: 6 September 2013; in revised form: 18 October 2013 / Accepted: 18 October 2013 / Published: 30 October 2013
Show/Hide Abstract | PDF Full-text (1177 KB) | HTML Full-text | XML Full-text

by , ,  and
Mar. Drugs 2013, 11(10), 3926-3950; doi:10.3390/md11103926
Received: 15 August 2013; in revised form: 22 September 2013 / Accepted: 27 September 2013 / Published: 16 October 2013
Show/Hide Abstract | PDF Full-text (568 KB) | HTML Full-text | XML Full-text

by , ,  and
Mar. Drugs 2013, 11(10), 3802-3822; doi:10.3390/md11103802
Received: 13 June 2013; in revised form: 6 September 2013 / Accepted: 22 September 2013 / Published: 11 October 2013
Show/Hide Abstract | Cited by 3 | PDF Full-text (740 KB) | HTML Full-text | XML Full-text | Supplementary Files
abstract graphic

by , , ,  and
Mar. Drugs 2013, 11(9), 3410-3424; doi:10.3390/md11093410
Received: 13 June 2013; in revised form: 5 August 2013 / Accepted: 12 August 2013 / Published: 6 September 2013
Show/Hide Abstract | PDF Full-text (782 KB) | HTML Full-text | XML Full-text | Supplementary Files

by , , , , , , , , ,  and
Mar. Drugs 2013, 11(9), 3224-3257; doi:10.3390/md11093224
Received: 23 July 2013; in revised form: 12 August 2013 / Accepted: 20 August 2013 / Published: 26 August 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (2340 KB) | HTML Full-text | XML Full-text
abstract graphic

by , , , , , , , , , , ,  and
Mar. Drugs 2013, 11(9), 3168-3185; doi:10.3390/md11093168
Received: 14 May 2013; in revised form: 9 August 2013 / Accepted: 9 August 2013 / Published: 26 August 2013
Show/Hide Abstract | Cited by 2 | PDF Full-text (1100 KB) | HTML Full-text | XML Full-text | Supplementary Files

by , , ,  and
Mar. Drugs 2013, 11(8), 3068-3076; doi:10.3390/md11083068
Received: 4 June 2013; in revised form: 9 July 2013 / Accepted: 30 July 2013 / Published: 21 August 2013
Show/Hide Abstract | Cited by 2 | PDF Full-text (413 KB) | HTML Full-text | XML Full-text | Supplementary Files

by , , , , , , ,  and
Mar. Drugs 2013, 11(7), 2625-2642; doi:10.3390/md11072625
Received: 6 June 2013; in revised form: 9 July 2013 / Accepted: 10 July 2013 / Published: 22 July 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (1174 KB) | HTML Full-text | XML Full-text

by , , , , , , ,  and
Mar. Drugs 2013, 11(7), 2574-2594; doi:10.3390/md11072574
Received: 9 April 2013; in revised form: 17 June 2013 / Accepted: 25 June 2013 / Published: 16 July 2013
Show/Hide Abstract | Cited by 3 | PDF Full-text (979 KB) | HTML Full-text | XML Full-text | Supplementary Files

by , , , , , , ,  and
Mar. Drugs 2013, 11(6), 1961-1976; doi:10.3390/md11061961
Received: 13 March 2013; in revised form: 22 May 2013 / Accepted: 27 May 2013 / Published: 10 June 2013
Show/Hide Abstract | Cited by 6 | PDF Full-text (1163 KB) | HTML Full-text | XML Full-text

Last update: 7 May 2014

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert